Toboroz
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
NCT07605416· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Hani Hassoun (principal investigator)
Toboroz
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
NCT07293247· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Daphna Y. Gelblum (principal investigator)
Toboroz
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07215910· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Lauren R. Schaff (principal investigator)
Toboroz
Malignant Polyp Registry
NCT07619079· Memorial Sloan Kettering Cancer Center· Forrás
Contact: Georgios Karagkounis, MD
Toboroz
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676· 1/2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Contact: Astellas Pharma Global Development, Inc
Toboroz
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
NCT07200830· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Deaglan McHugh (principal investigator)
Toboroz
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
NCT06900595· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Nitya P. Raj (principal investigator)
Toboroz
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Contact: Astellas Pharma Global Development, Inc.
Toboroz
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Carol Aghajanian (principal investigator)
Toboroz
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
NCT06931340· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Kristine P. Lacuna (principal investigator)
Toboroz
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Carol Aghajanian (principal investigator)
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· 3. fázis· NRG Oncology· Forrás
Contact: Justin M. Haseltine (principal investigator)
Toboroz
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
NCT07209449· 2. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Contact: Sminu Bose, MD
Toboroz
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· 3. fázis· NRG Oncology· Forrás
Contact: Marsha Reyngold (principal investigator)
Toboroz
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
NCT06484062· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: Tamanna Haque (principal investigator)
Toboroz
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
NCT07000084· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Eugene J. Pietzak (principal investigator)
Toboroz
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Justin M. Haseltine (principal investigator)
Toboroz
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Xin Wang (principal investigator)
Toboroz
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06589804· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Alan L. Ho (principal investigator)
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Darren R. Feldman (principal investigator)
Toboroz
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· 3. fázis· NRG Oncology· Forrás
Contact: Ying Liu (principal investigator)
Toboroz
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT06500481· 3. fázis· NRG Oncology· Forrás
Contact: Yao Yu (principal investigator)
Toboroz
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
NCT06807632· 1. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Contact: Jessica Ross, MD
Fut, nem toboroz
A Study of a Weight Loss Intervention in People With Endometrial Cancer
NCT06751589· Korai 1. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Toboroz
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: James Yoon (principal investigator)
Toboroz
A Study of Sotorasib in People With Non-Small Cell Lung Cancer
NCT06582771· 2. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Contact: Gregory Riely, MD, PhD
Toboroz
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Paul K. Paik (principal investigator)
Toboroz
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06022939· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Heather J. Landau (principal investigator)
Toboroz
A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
NCT06485778· 2. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Contact: Sean McBride, MD
Toboroz
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Martin R. Weiser (principal investigator)
Toboroz
A Study of Sacituzumab Govitecan in People With Mesothelioma
NCT06477419· 2. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Contact: Michael Offin, MD
Fut, nem toboroz
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: David H. Aggen (principal investigator)
Fut, nem toboroz
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
NCT06126341· Memorial Sloan Kettering Cancer Center· Forrás
Fut, nem toboroz
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
NCT05756777· 1. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Toboroz
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Vonetta M. Williams (principal investigator)
Toboroz
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· 3. fázis· NRG Oncology· Forrás
Contact: Jacob Shin (principal investigator)
Fut, nem toboroz
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Alison M. Schram (principal investigator)
Toboroz
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· 2. fázis· NRG Oncology· Forrás
Contact: Daniel Gorovets (principal investigator)
Fut, nem toboroz
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
NCT05607095· 1. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Contact: Lauren Banks, MD, PhD
Fut, nem toboroz
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
NCT05540392· 1/2. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Fut, nem toboroz
A Study of Cognitive Health in Survivors of Prostate Cancer
NCT05540782· Memorial Sloan Kettering Cancer Center· Forrás
Fut, nem toboroz
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
NCT05419076· 2. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Contact: Luke Pike, MD
Fut, nem toboroz
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT05092958· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
NCT05239624· 2. fázis· Memorial Sloan Kettering Cancer Center· Forrás
Showing 50 of 164.